Nicholas Y Ng

US Patent:

20190203301, Jul 4, 2019

Filed:

Jan 28, 2019

Appl. No.:

16/259419

Inventors:

- Basel, CH
HUAIXIANG HAO - MALDEN MA, US
MINDY HSIN-L HSIEH - SAN DIEGO CA, US
XIAOMO JIANG - Boston MA, US
JUN LIU - SAN DIEGO CA, US
NICHOLAS NG - SAN DIEGO CA, US

International Classification:

C12Q 1/6886
G01N 33/574
A61K 31/497

Abstract:

Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation mutation, phosphorylated LRP6, phophorylated Dishevelleds, and the expression of Frizzleds. These biomarkers can be associated with the better outcome for cancer patients treated with Wnt pathway inhibitors.

US Patent:

20180013193, Jan 11, 2018

Filed:

Jul 6, 2016

Appl. No.:

15/203494

Inventors:

- Mountain View CA, US
Nicholas Ng - Mountain View CA, US
Jing Liang - Mountain View CA, US
Dedi Haziza - Mountain View CA, US
Erik Stauffer - Mountain View CA, US

International Classification:

H01Q 1/28
H01Q 3/02
H01Q 1/48

Abstract:

A mobile platform includes an antenna adapted to simultaneously transmit on a first channel and receive on a second channel, and to dynamically switch communication channels as needed. For example, as the mobile platform changes position, orientation, etc., the configuration of the antenna may be updated to transmit on the second channel and receive on the first channel. Accordingly, despite changes in position or orientation, the mobile platform may maintain communication with other mobile platforms, ground controllers, user equipment, etc.

US Patent:

20170306409, Oct 26, 2017

Filed:

Dec 20, 2016

Appl. No.:

15/385088

Inventors:

- Basel, CH
Huaixiang HAO - Malden MA, US
Mindy Hsin-I HSIEH - San Diego CA, US
Xiaomo JIANG - Boston MA, US
Jun LIU - San Diego CA, US
Nicholas NG - San Diego CA, US

International Classification:

C12Q 1/68
G01N 33/574
A61K 31/497
G01N 33/574

Abstract:

Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation mutation, phosphorylated LRP6, phophorylated Dishevelleds, and the expression of Frizzleds. These biomarkers can be associated with the better outcome for cancer patients treated with Wnt pathway inhibitors.

US Patent:

20160024587, Jan 28, 2016

Filed:

Mar 10, 2014

Appl. No.:

14/774212

Inventors:

Jianwei CHE - San Diego CA, US
Jennifer HARRIS - San Diego CA, US
Hsin-I HSIEH - , US
Jie LI - San Diego CA, US
Jun LIU - San Diego CA, US
Nicholas NG - San Diego CA, US

International Classification:

C12Q 1/68
A61K 31/497

Abstract:

The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Wnt inhibitor, methods of determining the sensitivity of a cell to an Wnt inhibitor by measuring biomarkers, methods of screening for candidate Wnt inhibitor, Wnt inhibitor for use in head and neck squamous cell carcinoma.